• Therapeutic Cataract & Refractive
  • Lens Technology
  • Glasses
  • Ptosis
  • Comprehensive Eye Exams
  • AMD
  • COVID-19
  • DME
  • Ocular Surface Disease
  • Optic Relief
  • Geographic Atrophy
  • Cornea
  • Conjunctivitis
  • Myopia
  • Presbyopia
  • Allergy
  • Nutrition
  • Pediatrics
  • Retina
  • Cataract
  • Contact Lenses
  • Lid and Lash
  • Dry Eye
  • Glaucoma
  • Refractive Surgery
  • Comanagement
  • Blepharitis
  • OCT
  • Patient Care
  • Diabetic Eye Disease
  • Technology

Drug therapy improves prognosis of retinal vein blockage


Advances in pharmacotherapy, including intravitreal administration of corticosteroids and inhibitors of vascular endothelial growth factor, have improved management of retinal vein occlusions.

Optometrists can play an important role in optimizing patients' visual and general health prognosis by providing appropriate referral to a retinal specialist and the patient's primary-care provider for evaluation of possible underlying systemic disease, said Dr. Haynie, executive clinical director, Retina and Macula Specialists, Tacoma, WA.

Optometrists are often the first eye-care professionals to see patients with branch and central retinal vein occlusions (BRVO and CRVO, respectively). These patients develop a sudden, painless onset of vision loss. Either diagnosis carries a risk for permanent vision loss, but timely treatment and continued monitoring may reduce that risk, he said.

Accumulating experience indicates, however, that initiation of corticosteroid treatment for macular edema, or alternatives when corticosteroids are contraindicated, may hasten and improve visual recovery after BRVO.

"If the vision loss is related to capillary nonperfusion, it is likely to be permanent," Dr. Haynie said. "However, patients may be [treated with] brimonidine tartrate (Alphagan/Alphagan P, Allergan) for possible ischemic neuroprotection. Moreover, chronic macular edema is also a cause of permanent vision loss after BRVO, and the sooner resolution is achieved, the greater the likelihood of improving the final visual outcome.

Aggressive therapy

How aggressive one becomes with the pharmacologic treatment may be based on the severity of the condition, balancing the risks of treatment against its benefits. The least invasive treatment is to start topical corticosteroids or nonsteroidal anti-inflammatory drugs q.i.d. for 6 to 8 weeks. More aggressive treatment can also be considered, including a sub-Tenon's or intravitreal injection of triamcinolone acetonide or an anti-VEGF compound, such as bevacizumab or ranibizumab (Avastin or Lucentis, Genentech). Use of bevacizumab for this purpose is considered off-label.

Intravitreal triamcinolone has been reported to resolve macular edema in more than 80% of patients with BRVO. It can work rapidly, within a week in some cases, but it may take 6 to 8 weeks. In addition to a higher risk of elevated IOP and glaucoma, an intravitreal injection is associated with a higher incidence of cataracts, ptosis, and endophthalmitis.

"This low dose of acetazolamide is generally very safe. However, acetazolamide should not be used in patients with renal impairment, a known sulfa allergy, or a diabetic patient without first consulting the primary care provider," Dr. Haynie said.

Optometrists should also remember that 80% to 90% of patients with a BRVO have underlying systemic hypertension.

"Identifying hypertension and providing an appropriate referral can make a huge life difference in these patients," Dr. Haynie said.

Related Videos
Jacobi Cleaver, OD, FAAO
Jade Coats, OD, overviews a lecture on ocular pain and patient care
Jade Coats, OD, outlines two poster presentations she gave on a novel lipid-containing eye drop at the AOA Optometry's Meeting
Adam Alexander, OD, chats with Optometry Times about his AOA e-poster presentation on Miebo
Lorraine Provencher, MD, presenting slides
Megan Cavet, PhD
Nazlee Zebardast, MD, MSc, overviews her ARVO 2024 presentations on glaucoma and polygenic risk scores
© 2024 MJH Life Sciences

All rights reserved.